Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoquercetin + zafirlukast
- Development stage
- Unknown
- Lead developer
- Quercis Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Isoquercetin + zafirlukast** is an investigational oral small-molecule combination being developed by Quercis for cancer and thrombo-inflammatory indications. Isoquercetin is a protein disulfide-isomerase inhibitor, while zafirlukast is a repurposed cysteinyl leukotriene receptor 1 antagonist that also inhibits thiol isomerases including protein disulfide-isomerase A3. The combination is intended to cooperatively suppress tumor growth and tumor-associated thromboinflammation, including signaling associated with tissue factor, vascular endothelial growth factor, transmembrane protein 176B, and programmed cell death 1 ligand 1. Preclinical ovarian-cancer xenograft data support antitumor and antithrombotic activity, and Quercis lists Kinisoquin plus zafirlukast as an investigational oncology combination. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41474368/))
- Other names
- Isoquercin + zafirlukastKinisoquin + zafirlukastisoquercetin + zafirlukastzafirlukast + isoquercetin
02
Targets
P4HB (Protein disulfide-isomerase)CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)
Beyond the preview
Go deeper on isoquercetin + zafirlukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isoquercetin + zafirlukast.